434 related articles for article (PubMed ID: 17257744)
1. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers.
Huang B; Lei Z; Zhao J; Gong W; Liu J; Chen Z; Liu Y; Li D; Yuan Y; Zhang GM; Feng ZH
Cancer Lett; 2007 Jul; 252(1):86-92. PubMed ID: 17257744
[TBL] [Abstract][Full Text] [Related]
2. CCR2 expression by brain microvascular endothelial cells is critical for macrophage transendothelial migration in response to CCL2.
Dzenko KA; Song L; Ge S; Kuziel WA; Pachter JS
Microvasc Res; 2005 Jul; 70(1-2):53-64. PubMed ID: 15927208
[TBL] [Abstract][Full Text] [Related]
3. CCL2-independent role of CCR2 in immune responses against Leishmania major.
Quinones MP; Estrada CA; Jimenez F; Martinez H; Willmon O; Kuziel WA; Ahuja SK; Ahuja SS
Parasite Immunol; 2007 Apr; 29(4):211-7. PubMed ID: 17371458
[TBL] [Abstract][Full Text] [Related]
4. Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2.
Ringe J; Strassburg S; Neumann K; Endres M; Notter M; Burmester GR; Kaps C; Sittinger M
J Cell Biochem; 2007 May; 101(1):135-46. PubMed ID: 17295203
[TBL] [Abstract][Full Text] [Related]
5. Autocrine CCL2 promotes cell migration and invasion via PKC activation and tyrosine phosphorylation of paxillin in bladder cancer cells.
Chiu HY; Sun KH; Chen SY; Wang HH; Lee MY; Tsou YC; Jwo SC; Sun GH; Tang SJ
Cytokine; 2012 Aug; 59(2):423-32. PubMed ID: 22617682
[TBL] [Abstract][Full Text] [Related]
6. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds.
Lança T; Costa MF; Gonçalves-Sousa N; Rei M; Grosso AR; Penido C; Silva-Santos B
J Immunol; 2013 Jun; 190(12):6673-80. PubMed ID: 23686489
[TBL] [Abstract][Full Text] [Related]
7. Importance of CCL2-CCR2A/2B signaling for monocyte migration into spheroids of breast cancer-derived fibroblasts.
Ksiazkiewicz M; Gottfried E; Kreutz M; Mack M; Hofstaedter F; Kunz-Schughart LA
Immunobiology; 2010; 215(9-10):737-47. PubMed ID: 20605053
[TBL] [Abstract][Full Text] [Related]
8. Effects of the chemokine CCL2 on blood-brain barrier permeability during ischemia-reperfusion injury.
Dimitrijevic OB; Stamatovic SM; Keep RF; Andjelkovic AV
J Cereb Blood Flow Metab; 2006 Jun; 26(6):797-810. PubMed ID: 16192992
[TBL] [Abstract][Full Text] [Related]
9. Involvement of CC chemokines in gammadelta T lymphocyte trafficking during allergic inflammation: the role of CCL2/CCR2 pathway.
Penido C; Costa MF; Souza MC; Costa KA; Candéa AL; Benjamim CF; Henriques Md
Int Immunol; 2008 Jan; 20(1):129-39. PubMed ID: 18056919
[TBL] [Abstract][Full Text] [Related]
10. Constitutive neuronal expression of CCR2 chemokine receptor and its colocalization with neurotransmitters in normal rat brain: functional effect of MCP-1/CCL2 on calcium mobilization in primary cultured neurons.
Banisadr G; Gosselin RD; Mechighel P; Rostène W; Kitabgi P; Mélik Parsadaniantz S
J Comp Neurol; 2005 Nov; 492(2):178-92. PubMed ID: 16196033
[TBL] [Abstract][Full Text] [Related]
11. An engineered GM-CSF-CCL2 fusokine is a potent inhibitor of CCR2-driven inflammation as demonstrated in a murine model of inflammatory arthritis.
Rafei M; Berchiche YA; Birman E; Boivin MN; Young YK; Wu JH; Heveker N; Galipeau J
J Immunol; 2009 Aug; 183(3):1759-66. PubMed ID: 19592643
[TBL] [Abstract][Full Text] [Related]
12. Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?
Fei L; Ren X; Yu H; Zhan Y
Front Immunol; 2021; 12():771210. PubMed ID: 34804061
[TBL] [Abstract][Full Text] [Related]
13. A novel activator of C-C chemokine, FROUNT, is expressed with C-C chemokine receptor 2 and its ligand in failing human heart.
Satoh M; Akatsu T; Ishkawa Y; Minami Y; Nakamura M
J Card Fail; 2007 Mar; 13(2):114-9. PubMed ID: 17395051
[TBL] [Abstract][Full Text] [Related]
14. Myeloid NEMO deficiency promotes tumor immunosuppression partly via MCP1-CCR2 axis.
Yuanyuan L; Yakun L; Zhongyao L; Le Y; Weisong D; Moran G; Hui B; Chunyan L
Exp Cell Res; 2021 Feb; 399(2):112467. PubMed ID: 33428904
[TBL] [Abstract][Full Text] [Related]
15. Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model.
Teng KY; Han J; Zhang X; Hsu SH; He S; Wani NA; Barajas JM; Snyder LA; Frankel WL; Caligiuri MA; Jacob ST; Yu J; Ghoshal K
Mol Cancer Ther; 2017 Feb; 16(2):312-322. PubMed ID: 27980102
[TBL] [Abstract][Full Text] [Related]
16. Blocking mast cell-mediated type I hypersensitivity in experimental allergic conjunctivitis by monocyte chemoattractant protein-1/CCR2.
Tominaga T; Miyazaki D; Sasaki S; Mihara S; Komatsu N; Yakura K; Inoue Y
Invest Ophthalmol Vis Sci; 2009 Nov; 50(11):5181-8. PubMed ID: 19553621
[TBL] [Abstract][Full Text] [Related]
17. A novel recombinant fusion protein encoding a 20-amino acid residue of the third extracellular (E3) domain of CCR2 neutralizes the biological activity of CCL2.
Izhak L; Wildbaum G; Zohar Y; Anunu R; Klapper L; Elkeles A; Seagal J; Yefenof E; Ayalon-Soffer M; Karin N
J Immunol; 2009 Jul; 183(1):732-9. PubMed ID: 19535619
[TBL] [Abstract][Full Text] [Related]
18. CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases.
Craig MJ; Loberg RD
Cancer Metastasis Rev; 2006 Dec; 25(4):611-9. PubMed ID: 17160712
[TBL] [Abstract][Full Text] [Related]
19. Tumor-conditioned Gr-1(+)CD11b(+) myeloid cells induce angiogenesis through the synergistic action of CCL2 and CXCL16 in vitro.
Han EC; Lee J; Ryu SW; Choi C
Biochem Biophys Res Commun; 2014 Jan; 443(4):1218-25. PubMed ID: 24388986
[TBL] [Abstract][Full Text] [Related]
20. Human periosteum-derived progenitor cells express distinct chemokine receptors and migrate upon stimulation with CCL2, CCL25, CXCL8, CXCL12, and CXCL13.
Stich S; Loch A; Leinhase I; Neumann K; Kaps C; Sittinger M; Ringe J
Eur J Cell Biol; 2008 Jun; 87(6):365-76. PubMed ID: 18501472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
